Mass Spectrometry & Spectroscopy
First NMR Analyser Designed Specifically for the Clinical Laboratory
Nov 16 2012
Agilent Technologies Inc have announced that it has entered into an exclusive supply agreement with LipoScience Inc to provide nuclear magnetic resonance (NMR) components for LipoScience’s Vantera Clinical Analyser. The analyser is the first fully-automated NMR diagnostic platform designed specifically for the clinical laboratory and cleared by the US Food and Drug Administration.
The Vantera Clinical Analyser, which recently received 510(k) clearance from the FDA, combines proprietary signal-processing algorithms and NMR spectroscopic detection to identify and quantify concentrations of lipoproteins and, potentially, small-molecule metabolites.
“We are extraordinarily pleased to join forces with LipoScience to provide key components for this leading-edge diagnostic platform,” said Nick Roelofs, President of Agilent’s Life Sciences Group.
“LipoScience is pioneering a new field of personalised diagnostics based on NMR technology. Broadening access to our proprietary diagnostic tests is central to our vision of becoming a clinical standard of care. We value Agilent’s NMR expertise and look forward to partnering with them in our efforts to decentralise our NMR clinical analyser to leading clinical laboratories and academic centres of excellence,” added Richard O. Brajer, CEO of LipoScience.
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark